CXO is still a track with strong performance growth and certainty in the pharmaceutical sector

[Pharmaceutical Network Market Analysis] With the transfer of global pharmaceutical outsourcing and the release of domestic and foreign outsourcing demand, China's pharmaceutical outsourcing has a large room for growth in the future, and the industry will present a pattern of "one superpower, many strong, and polarization"
.

The CXO sector performed well in the Q1 quarterly report window of 2022.
WuXi AppTec, Pharmaron, Tigermed, Zhaoyan New Drug, Asymchem, Proton, Medicil, and Jiuzhou Pharmaceutical all delivered beautiful performances.
's transcript
.

Data show that Asymchem’s main revenue in the first quarter was 2.
062 billion yuan, up 165.
28% year-on-year; net profit attributable to the parent was 499 million yuan, up 223.
59% year-on-year; non-net profit deducted was 486 million yuan, up 275.
76% year-on-year
.

The operating income of WuXi AppTec in the first quarter was 8.
474 billion yuan, a year-on-year increase of 71.
2%; the net profit attributable to shareholders of the listed company was 1.
643 billion yuan, a year-on-year increase of 9.
5%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.
714 billion yuan, a year-on-year increase of 106.
52%
.

Jiuzhou Pharmaceutical achieved operating income of 1.
374 billion yuan in the first quarter, a year-on-year increase of 60.
46%; net profit of 208 million yuan, a year-on-year increase of 120.
13%; basic earnings per share of 0.
25 yuan
.

 　　Analysts said that from a long-term perspective, first-tier stocks such as WuXi AppTec and Asymchem will still have strong global competitiveness
.

Among them, WuXi PharmaTech expects that the company will still achieve rapid growth of 63%-65% in the second quarter of 2022, and it is also confident in the goal of 65%-70% revenue growth for the whole year of 2022
.

 　　It is understood that starting from the third quarter of last year, WuXi AppTec has adjusted the organizational structure of the company's business segments, integrating end-to-end integrated service capabilities into the three new business segments of chemistry, biology and testing
.

At present, there are five business segments: chemical business segment, biology business segment, testing business segment, cell and gene therapy, and domestic new drug research and development service department.

.

 　　In answering questions from investors recently, Asymchem said that due to factors such as the increase in the number of global drug research pipelines and the overall increase in the penetration rate of outsourcing, the CDMO industry is booming, the company is operating well, and it has achieved sustainable development
.

In the future, the company will continue to promote the steady growth of the core small molecule CDMO business, adhering to the strategy of deepening the small molecule business and expanding the small and medium-sized customers to expand the global market share.
Pay equal attention to external mergers and acquisitions, and promote the rapid expansion of strategic emerging businesses
.

 　　Analysts pointed out that the high growth of CXO companies in the short and medium term has strong certainty
.

In the medium and long term, according to industry prosperity indicators such as investment and financing activity in the primary market and corporate R&D expenditures, the industry believes that with the rise of some innovative drugs and emerging therapies, the related CXO business will bring considerable growth to the industry.
Market, continue to ensure high performance growth and promote the industry's high prosperity
.

 　　It is reported that Asymchem and Proton have successively obtained large orders from multinational pharmaceutical companies; the orders in hand of Zhaoyan New Drug and Tigermed have hit a record high; WuXi Biologics is also actively developing emerging businesses such as vaccines and ADC drugs CDMO.
, in order to obtain more large international orders
.

With sufficient orders in hand, strong demand for R&D in the industry, and good overseas market expansion.
.
.
With good performance, CXO is still a track with strong performance growth and certainty in the pharmaceutical sector
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.